Multivariate analysis
| . | Oral BuCy vs Cy/TBI RR (95% CI) . | IV BuCy vs Cy/TBI RR (95% CI) . | Oral BuCy vs IV BuCy RR (95% CI) . | Overall P value . |
|---|---|---|---|---|
| aGVHD III-IV* | 0.72 (0.53-0.98) | 0.72 (0.51-1.02) | 1.00 (0.67-1.49) | .048 |
| cGVHD† | 1.01 (0.73-1.39) | 1.13 (0.87-1.47) | 0.89 (0.58-1.37) | .65 |
| NRM‡ | 0.72 (0.52-1.01) | 0.58 (0.39-0.86) | 1.24 (0.79-1.95) | .011 |
| Relapse (≤1 y)§ | 0.81 (0.59-1.11) | 1.06 (0.76-1.49) | 0.76 (0.52-1.12) | .31 |
| Relapse (>1 y)§ | 1.22 (0.78-1.90) | 0.24 (0.084-0.66) | 5.19 (1.85-14.57) | .0074 |
| LFS‖ | 0.87 (0.72-1.06) | 0.70 (0.55-0.88) | 1.25 (0.96-1.62) | .0096 |
| OS‖ | 0.78 (0.60-1.01) | 0.68 (0.52-0.88) | 1.15 (0.85-1.56) | .0084 |
| . | Oral BuCy vs Cy/TBI RR (95% CI) . | IV BuCy vs Cy/TBI RR (95% CI) . | Oral BuCy vs IV BuCy RR (95% CI) . | Overall P value . |
|---|---|---|---|---|
| aGVHD III-IV* | 0.72 (0.53-0.98) | 0.72 (0.51-1.02) | 1.00 (0.67-1.49) | .048 |
| cGVHD† | 1.01 (0.73-1.39) | 1.13 (0.87-1.47) | 0.89 (0.58-1.37) | .65 |
| NRM‡ | 0.72 (0.52-1.01) | 0.58 (0.39-0.86) | 1.24 (0.79-1.95) | .011 |
| Relapse (≤1 y)§ | 0.81 (0.59-1.11) | 1.06 (0.76-1.49) | 0.76 (0.52-1.12) | .31 |
| Relapse (>1 y)§ | 1.22 (0.78-1.90) | 0.24 (0.084-0.66) | 5.19 (1.85-14.57) | .0074 |
| LFS‖ | 0.87 (0.72-1.06) | 0.70 (0.55-0.88) | 1.25 (0.96-1.62) | .0096 |
| OS‖ | 0.78 (0.60-1.01) | 0.68 (0.52-0.88) | 1.15 (0.85-1.56) | .0084 |
Other significant factors in the multivariate model are noted by symbol. Bold indicates P value < .05. aGVHD, acute GVHD; cGVHD, chronic GVHD.
*Sex, donor type.
Donor type, recipient age, donor and recipient sex match, and graft type.
Recipient age, KPS, donor type, time from diagnosis to transplant.
KPS and Cytogenetic risk group.
Recipient age, KPS, donor type, Cytogenetic risk group.